VANQUISH-2
41 evidence topics · 16 sources
Objective
Study objective in the ClinicalTrials.gov record
Cardiometabolic hypothesis in the congress abstract
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-06-23” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-07-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-08-05” (opens the source at this quote in a new tab)
“Last Update Posted 2026-04-07” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Number of randomizing sites in the baseline poster
Expected completion and timing of data
Study design
Design, duration, randomization ratio, and stratification
Official title in the ClinicalTrials.gov record
Allocation of fewer participants to the lowest dose
Extension study after the 78-week treatment period
Eligibility criteria
Key inclusion and exclusion criteria in the design poster
“Adults ≥18 years of age” (opens the source at this quote in a new tab)
“BMI ≥27 kg/m2” (opens the source at this quote in a new tab)
“Prior or planned bariatric surgery” (opens the source at this quote in a new tab)
“History of acute or chronic pancreatitis” (opens the source at this quote in a new tab)
Key criteria in the congress abstract
Inclusion criteria and permitted background glucose-lowering therapy in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |
Subcutaneous formulation: dose arms, time at target dose, and lifestyle counseling
Subcutaneous formulation: dose titration from 1.25 mg
Subcutaneous formulation: transition from vial and syringe to autoinjector
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint
Secondary endpoint: categorical weight reduction
Glycemic and cardiometabolic outcomes and adjudicated safety events
Additional outcomes: function, cardiometabolic health, mental health, and work productivity
Rationale stated in the design poster and the baseline poster
Regulatory basis for the primary endpoint and for glycemic secondary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Randomized participants per arm in the baseline poster
| Arm | Randomized participants |
|---|---|
| Placebo | “N=276” |
| VK2735 7.5 mg | “N=185” |
| VK2735 12.5 mg | “N=276” |
| VK2735 17.5 mg | “N=276” |
| Total | “1013 participants were randomized from 127 U.S. study sites” |
Enrollment reported after completion
Description of analysis sets
Population analyzed for baseline characteristics
Efficacy and safety analysis sets
No evidence found.
Results
Participant disposition
Blinded discontinuation rate across the VANQUISH program
Baseline characteristics
Demographics and body size compared with NHANES
| Characteristic | VANQUISH-2 (N=1013) | NHANES |
|---|---|---|
| Age, mean (SD), years | “58.3 (11.5)” | “59.51 (11.7)” |
| Age 65 years or older | “31%” | “38%” |
| Sex, female to male, % | “49:51” | “49:51” |
| Weight, mean (SD), kg | “105.3 (23.5)” | “99.8 (20.2)” |
| Waist circumference, mean (SD), cm | “118.2 (15.8)” | “116.4 (12.6)” |
| BMI, mean (SD), kg/m2 | “37.1 (7.1)” | “35.7 (6.2)” |
| BMI 27 to less than 30 kg/m2 | “13%” | “22%” |
| BMI 30 to less than 35 kg/m2 | “32%” | “34%” |
| BMI 35 to less than 40 kg/m2 | “26%” | “22%” |
| BMI 40 kg/m2 or higher | “29%” | “22%” |
Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration
Representativeness stated by the authors
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations evident from the available VANQUISH-2 documents
VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.
Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).
The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.